The protein is implicated in a wide swath of cancers, but harnessing it for drug R&D is still a major scientific challenge.

Roswell Park researchers present a two-step, mechanism-based drug strategy at AACR 2026 that selectively targets cancers with ...

The gene p53 acts as a tumor suppressor and often is called the ‘guardian of the genome.’ This gene is central to maintaining genomic stability, which prevents mutations from accumulating and leading ...

Proteins that are frequently altered in tumors play a prominent role in cancer research. The protein RFX7, a largely unknown transcription factor, has recently been linked to lymph node cancer.

Researchers in the lab of Michael Sigal at the Max Delbrück Center and Charité – Universitätsmedizin Berlin have elucidated the role of the p53 gene in ulcerative colitis. The study, published in ...

The p53 gene status (mutation) and protein alterations (nuclear accumulation detectable by immunohistochemistry; p53 protein status) are associated with bladder cancer progression. Substantial ...

The results of research headed by a team in the lab of Michael Sigal, MD, at the Max Delbrück Center and Charité—Universitätsmedizin Berlin, have shed new light on the role of the p53 tumor suppressor ...

Autologous T-Cell Therapies in Solid Tumor Malignancies: Current Landscape and Future Opportunities Histology-agnostic therapies: by focusing on common mutations across various cancers, this approach ...

As we age, our cells accumulate genetic changes—mutations—some of which open the door to cancer. Scientists call these ...